Evidence map›Paper›PMID 37385117›Full record

ArticleDrug and alcohol dependence2023

Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome.

Julia Tobacyk, Brian J Parks, Paloma Salazar, Lori U Coward, Michael D Berquist, Gregory S Gorman, Lisa K Brents

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug and alcohol dependence, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Julia TobacykDepartment of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, 4301 W. Markham Street, Mail Slot 611, Little Rock, AR72205, USA.
Brian J ParksDepartment of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, 4301 W. Markham Street, Mail Slot 611, Little Rock, AR72205, USA.
Paloma SalazarDepartment of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, 4301 W. Markham Street, Mail Slot 611, Little Rock, AR72205, USA.
Lori U CowardDepartment of Pharmaceutical Sciences in the McWhorter School of Pharmacy at Samford University, 800 Lakeshore Dr, Birmingham, AL35229, USA.
Michael D BerquistDepartment of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, 4301 W. Markham Street, Mail Slot 611, Little Rock, AR72205, USA.
Gregory S GormanDepartment of Pharmaceutical Sciences in the McWhorter School of Pharmacy at Samford University, 800 Lakeshore Dr, Birmingham, AL35229, USA.
Lisa K BrentsDepartment of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, 4301 W. Markham Street, Mail Slot 611, Little Rock, AR72205, USA. Electronic address: lbrents@uams.edu.
University of Arkansas for Medical Sciences · USSamford University · US

Funding

Expanding Translational Research in ArkansasUL1TR003107 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI JAMES, LAURA P · 2019 to 2023
$21.6M
Translational Training in AddictionT32DA022981 · NIDA · UNIV OF ARKANSAS FOR MED SCIS · PI Melissa Jean Zielinski · 2009 to 2026
$6.1M
J. NRSA TrainingTL1TR003109 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI SEXTON, KEVIN WAYNE · 2019 to 2023
$1.5M
NCATS NIH HHS TL1 TR003109NCATS NIH HHS UL1 TR003107NIDA NIH HHS T32 DA022981
6 · The paper itself

Abstract

Buprenorphine (BUP) is the preferred treatment for opioid use disorder during pregnancy but can cause neonatal opioid withdrawal syndrome (NOWS). Norbuprenorphine (NorBUP), an active metabolite of BUP, is implicated in BUP-associated NOWS. We hypothesized that BUP, a low-efficacy agonist of mu opioid receptors, will not antagonize NorBUP, a high-efficacy agonist of mu opioid receptors, in producing NOWS. To test this hypothesis, we treated pregnant Long-Evans rats with BUP (0, 0.01, 0.1 or 1mg/kg/day) ± NorBUP (1mg/kg/day) from gestation day 9 until pup delivery, and tested pups for opioid dependence using our established NOWS model. We used LC-MS-MS to quantify brain concentrations of BUP, NorBUP, and their glucuronide conjugates. BUP had little effect on NorBUP-induced NOWS, with the exception of 1mg/kg/day BUP significantly increasing NorBUP-induced NOWS by 58% in females. BUP and NorBUP brain concentrations predicted NOWS in multiple linear regression models. Interestingly, NorBUP contributed more to NOWS in females (β

Indexed as

BuprenorphineNeonatal Abstinence SyndromeOpioid-Related DisordersAnalgesics, OpioidAnimalsFemaleHumansInfant, NewbornMalePregnancyRatsRats, Long-EvansReceptors, Opioid, muAnalgesics, OpioidBuprenorphinenorbuprenorphineReceptors, Opioid, muBuprenorphineNeonatal opioid withdrawal syndromeNorbuprenorphineOpioid use disorderPregnancy

Identifiers

PMID37385117
PMCPMC10573081
OpenAlexW4381486996

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.